Citius Pharmaceuticals, Inc.

Nasdaq:CTXR

Pharmaceutical Preparations·CRANFORD, NJ

CEO

Mazur Leonard L

CFO

Bartushak Jaime

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q4 2025	12/31/25	2/13/26	→
10-K/A	FY 2025	9/30/25	1/28/26	→
10-K	FY 2025	9/30/25	12/23/25	→
10-Q	Q2 2025	6/30/25	8/12/25	→
10-Q	Q1 2025	3/31/25	5/14/25	→
10-Q	Q4 2024	12/31/24	2/14/25	→
↓

Earnings Releases (8-K)

17 shown

Filed	Period
2/13/26	Q2 FY2026	→
12/23/25	Q1 FY2026	→
8/12/25	Q4 FY2025	→
5/14/25	Q3 FY2025	→
12/27/24	Q1 FY2025	→
8/12/24	Q4 FY2024	→
↓

News (8-K)

63 shown

Filed	Type	Description
3/4/26	Other	Other Events	→
12/1/25	Reg FD	Regulation FD Disclosure	→
10/23/25	Reg FD	Regulation FD Disclosure	→
10/21/25	Agreement	Entry into a Material Definitive Agreement	→
7/8/25	Other	Other Events	→
6/12/25	Agreement	Entry into a Material Definitive Agreement	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
2/24/26	ARS	FORM ARS	→
10/21/25	424B5	PROSPECTUS SUPPLEMENT	→
6/11/25	424B5	PROSPECTUS SUPPLEMENT	→
4/2/25	424B5	PROSPECTUS SUPPLEMENT	→
1/27/25	ARS	FORM ARS	→
1/8/25	424B5	PROSPECTUS SUPPLEMENT	→
↓

Filing History(616 filings)

TypeDateAccessionPeriodSize

8-K

Mar 4, 2026

0001213900-26-023439CURRENT REPORT

Mar 4, 2026

313.0 KB

ARS

Feb 24, 2026

0001213900-26-019569FORM ARS

Sep 30, 2025

1.3 MB

DEFA14A

Feb 24, 2026

0001213900-26-019568DEFINITIVE ADDITIONAL MATERIALS

—

1.5 MB

DEF 14A

Feb 24, 2026

0001213900-26-019566DEFINITIVE PROXY STATEMENT

Apr 6, 2026

3.2 MB

SCHEDULE 13G/A

Feb 17, 2026

0001649553-26-000024

—

12.0 KB

8-K

Feb 13, 2026

0001213900-26-015895CURRENT REPORT

Feb 9, 2026

311.7 KB

10-Q

Feb 13, 2026

0001213900-26-015878QUARTERLY REPORT

Dec 31, 2025

5.0 MB

10-K/A

Jan 28, 2026

0001213900-26-008861AMENDMENT NO. 1 TO FORM 10-K

Sep 30, 2025

554.7 KB

8-K

Dec 23, 2025

0001213900-25-125413CURRENT REPORT

Dec 23, 2025

299.0 KB

10-K

Dec 23, 2025

0001213900-25-125333ANNUAL REPORT

Sep 30, 2025

7.0 MB

SCHEDULE 13D/A

Dec 17, 2025

0001213900-25-122793

—

7.8 KB

8-K

Dec 1, 2025

0001213900-25-116760CURRENT REPORT

Dec 1, 2025

20.9 MB

SCHEDULE 13G

Oct 27, 2025

0001649553-25-000174

—

15.7 KB

8-K

Oct 23, 2025

0001213900-25-101741CURRENT REPORT

Oct 23, 2025

49.2 MB

8-K

Oct 21, 2025

0001213900-25-100847CURRENT REPORT

Oct 20, 2025

917.4 KB

424B5

Oct 21, 2025

0001213900-25-100559PROSPECTUS SUPPLEMENT

—

381.3 KB

Sep 23, 2025

0001213900-25-090602

Aug 8, 2025

25.2 KB

SCHEDULE 13D/A

Sep 12, 2025

0001213900-25-087227

—

7.9 KB

Aug 12, 2025

0001213900-25-075035

Aug 8, 2025

30.6 KB

8-K

Aug 12, 2025

0001213900-25-075034CURRENT REPORT

Aug 12, 2025

287.1 KB

10-Q

Aug 12, 2025

0001213900-25-074997QUARTERLY REPORT

Jun 30, 2025

4.5 MB

SCHEDULE 13D/A

Jul 25, 2025

0001213900-25-067797

—

6.6 KB

8-K

Jul 8, 2025

0001213900-25-062099CURRENT REPORT

Jul 7, 2025

196.2 KB

8-K

Jun 12, 2025

0001213900-25-053607CURRENT REPORT

Jun 9, 2025

875.5 KB

424B5

Jun 11, 2025

0001213900-25-053274PROSPECTUS SUPPLEMENT

—

381.4 KB

25 filings shown

Citius Pharmaceuticals, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(616 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/24/26	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
2/24/26	DEF 14A	DEFINITIVE PROXY STATEMENT	→
4/28/25	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
4/28/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
4/18/25	PRE 14A	PRELIMINARY PROXY STATEMENT	→
1/27/25	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
↓

Filed	Form	Description
9/23/25	4	4	→
8/12/25	4	4	→
11/27/24	SC 13D/A	AMENDMENT NO. 2 TO SCHEDULE 13D	→
11/12/24	4	4	→
11/12/24	4	4	→
11/12/24	4	4	→
↓

Filed	Form	Description
2/17/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
12/17/25	SCHEDULE 13D/A	SCHEDULE 13D/A	→
10/27/25	SCHEDULE 13G	SCHEDULE 13G	→
9/12/25	SCHEDULE 13D/A	SCHEDULE 13D/A	→
7/25/25	SCHEDULE 13D/A	SCHEDULE 13D/A	→
3/1/24	EFFECT	EFFECT	→
↓